Alexza’s Inhaled Antipsychotic May Pose Lung Risks, FDA Says

Alexza Pharmaceuticals’ inhaled antipsychotic drug may pose lung risks, according to U.S. regulators considering whether to approve the treatment for sale.
Businessweek